The next generation of treatment for hepatitis c
Download
1 / 22

The next generation of Treatment for Hepatitis C - PowerPoint PPT Presentation


  • 79 Views
  • Updated On :

The next generation of Treatment for Hepatitis C. Treatment of CHC: Outcomes. Goal of therapy is to render the patient PCR negative for HCV RNA Need to remain PCR negative 6 months after end of therapy Response rates for combination therapy Genotype 1 up to 40% Genotypes 2 or 3 up to 80%.

Related searches for The next generation of Treatment for Hepatitis C

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'The next generation of Treatment for Hepatitis C' - jerry


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Treatment of chc outcomes l.jpg
Treatment of CHC: Outcomes

  • Goal of therapy is to render the patient PCR negative for HCV RNA

  • Need to remain PCR negative 6 months after end of therapy

  • Response rates for combination therapy

    • Genotype 1 up to 40%

    • Genotypes 2 or 3 up to 80%


Evolution of hcv genotype 1 treatment l.jpg
Evolution of HCV genotype 1 treatment

100

80

  • 42–54%

Peg-IFN + RBV2–4

  • 16–28%

60

IFN + RBV1

SVR rate (%)

  • 2–7%

IFN1

40

20

1990

2000

2020

2010

  • IFN: interferon; RBV: ribavirin Peg-IFN: peginterferonDAA: direct-acting antiviralSVR: sustained virologic response

1. McHutchison JG, et al. N Engl J Med 1998;339:1485–92; 2. Fried M, et al. N Engl J Med 2002;347:975–823. Manns MP, et al. Lancet 2001;358:958–65; 4. Hadziyannis SJ, et al. Ann Intern Med 2004;140:346–555. Jacobson IM, et al. Hepatology 2010;52(Suppl):427A; 6. Sherman KE, et al. Hepatology 2010;52(Suppl.):401A7. Poordad F, et al. Hepatology 2010;52(Suppl.):402A; 8. Foster GR, et al. Hepatol Int 2011;5(Suppl.1):14


Treatment issues l.jpg
Treatment Issues

  • Genotypes 2/3 – nothing new on horizon

  • Genotype 1 – failure rate 50-60%

  • No good options for treatment failures



Direct acting anivirals daas l.jpg
Direct Acting Anivirals (DAAs)

  • DAA-based triple combination therapy led to improved SVR rates over current therapy in Phase II trials

    • 61–85% SVR with telaprevir-based therapy4–6

    • 54–75% SVR with boceprevir-based therapy7

  • Telaprevir and boceprevir have recently completed Phase III trials in treatment-naïve patients

    • Telaprevir: ADVANCE8 and ILLUMINATE9

    • Boceprevir: SPRINT-210


Advance telaprevir study design n 1088 l.jpg

Pbo +

PR

TVR

+

PR

PR

PR

PR

PR

Pbo + PR

TVR + PR

PR

ADVANCE (telaprevir): study design (N=1088)

PR48 (control)(N=361)

SVR

Follow-up

SVR

eRVR+

Follow-up

Follow-up

T12PR(N=363)

eRVR–

SVR

Follow-up

SVR

eRVR+

Follow-up

Follow-up

T8PR(N=364)

SVR

eRVR–

Follow-up

0

8

12

24

36

48

72

Weeks

Peg-IFN alfa-2a dose: 180 µg/week; RBV dose: 1000 or 1200 mg/dayeRVR: extended rapid virologic response (undetectable HCV RNA at Weeks 4 and 12); Pbo: placebo; PR: peginterferon/ribavirin; TVR: telaprevir

Jacobson IM, et al. Hepatology 2010;52(Suppl.):427A


Sprint 2 boceprevir study design n 1097 l.jpg

SVR

SVR

SVR

SVR

PRlead-in

PRlead-in

PRlead-in

Follow-up

PR + Placebo

Follow-up

Follow-up

Follow-up

PR + Boceprevir

PR + Boceprevir

PR + Placebo

SPRINT-2 (boceprevir): study design (N=1097)

PR48 ControlN=363

Weeks 8–24 HCV RNA undetectable

BOC

RGT

N=368

Weeks 8–24 HCV RNA detectable*

BOC44/

PR48

N=366

24

28

0

4

8

48

72

Weeks

*But with undetectable HCV RNA at Week 24

Peg-IFN alfa-2b dose: 1.5 µg/kg/week

RBV dose: 600–1400 mg/day in a divided daily doseRGT: response-guided therapy

Poordad F, et al. Hepatology 2010;52(Suppl.):402A


Illuminate telaprevir study design n 540 l.jpg

eRVR+

T12PR48N=160

eRVR+

T12PR24

N=162

eRVR–

T12PR48

N=118

PR

PR

PR

T12PR

PR

ILLUMINATE (telaprevir): study design (N=540)

SVR

72 weeks

Follow-up

Follow-up

Non-inferiority (NI)

Randomized Treatments

eRVR+

SVR

Follow-up

Assigned Treatment

SVR

eRVR–

Follow-up

0 12 20

20 24 36 48 60 72

Weeks

Patients discontinued for any reason before Week 20 randomization were categorized as ‘Other’ (N=100)Stopping rules were similar to ADVANCE

Sherman KE, et al. Hepatology 2010;52(Suppl.):401A


Advance and illuminate svr rates with telaprevir based therapy versus pr alone l.jpg
ADVANCE and ILLUMINATE: SVR rates with telaprevir-based therapy versus PR alone

72–75*

T12PR

659/903

PR48

158/361

Jacobson IM, et al. Hepatology 2010;52(Suppl.):427A; Sherman KE, et al. CROI 2011. Abstract 957

*p<0.0001 vs PR48 in ADVANCE (75% versus 44%)


Sprint 2 svr rates with boceprevir based therapy versus pr alone l.jpg
SPRINT-2: SVR rates with boceprevir-based therapy versus PR alone

BOC44/PR48

242/366

PR48

137/363

BOC RGT

233/368

For non-Black patients, p<0.0001 for both boceprevir arms versus PR48; for Black patients, p=0.044 and p=0.004 for BOC RGT and BOC44/PR48, respectively, versus PR48

Adapted from Poordad F, et al. Hepatology 2010;52(Suppl.):402A


Tripple therapy works in advanced fibrosis advance telaprevir svr rates by fibrosis stage l.jpg
Tripple therapy works in advanced fibrosis aloneADVANCE (telaprevir): SVR rates by fibrosis stage

ADVANCE1

No, minimal or portal fibrosis

Bridging fibrosis or cirrhosis

SVR (%)

PR48134/288

T12PR226/290

PR4824/73

T12PR45/73

n/N=

1. Jacobson IM, et al. Hepatology 2010;52(Suppl.):427A;


Tripple therapy works in all il28b genotypes advance telaprevir svr rates by il28b genotype l.jpg
Tripple therapy works in all IL28B genotypes aloneADVANCE (telaprevir): SVR rates by IL28B genotype

CC

CT

TT

SVR (%)

PR4820/80

T12PR48/68

PR4835/55

T12PR45/50

PR486/26

T12PR16/22

n/N=

Samples were available for 454/1088 (42%) patients enrolled in ADVANCE

Jacobson IM, et al. J Hepatol 2011;54(Suppl.):S542


Safety and tolerability with daas l.jpg
Safety and tolerability with DAAs alone

  • Common AEs with PR include:1–3

    • Fatigue, headache, nausea, pyrexia and myalgia

    • Anemia and neutropenia

    • Depression, irritability and insomnia

    • Rash

  • Additional management considerations with DAAs

    • Telaprevir:4–6 rash, anemia

    • Boceprevir:7,8 anemia and dysgeusia

1. Pegintron EMA Summary of Product Characteristics; 2. Pegasys EMA Summary of Product Characteristics3. Rebetol EMA Summary of Product Characteristics; 4. Jacobson IM, et al. Hepatology 2010;52(Suppl.):427A

5. Sherman KE, et al. Hepatology 2010;52(Suppl.):401A; 6. Foster GR, et al. Hepatol Int 2011;5(Suppl. 1):147. Poordad F, et al. Hepatology 2010;52(Suppl.):402A; 8. Bacon BR, et al. Hepatology 2010;52(Suppl.):430A

AE: adverse event


Evolution of hcv genotype 1 treatment15 l.jpg
Evolution of HCV genotype 1 treatment alone

100

  • 59–75%

DAA+Peg-IFN + RBV5–8

80

  • 42–54%

Peg-IFN + RBV2–4

  • 16–28%

60

IFN + RBV1

SVR rate (%)

  • 2–7%

IFN1

40

20

1990

2000

2020

2010

  • IFN: interferon; RBV: ribavirin Peg-IFN: peginterferonDAA: direct-acting antiviralSVR: sustained virologic response

1. McHutchison JG, et al. N Engl J Med 1998;339:1485–92; 2. Fried M, et al. N Engl J Med 2002;347:975–823. Manns MP, et al. Lancet 2001;358:958–65; 4. Hadziyannis SJ, et al. Ann Intern Med 2004;140:346–555. Jacobson IM, et al. Hepatology 2010;52(Suppl):427A; 6. Sherman KE, et al. Hepatology 2010;52(Suppl.):401A7. Poordad F, et al. Hepatology 2010;52(Suppl.):402A; 8. Foster GR, et al. Hepatol Int 2011;5(Suppl.1):14



Definitions of failure on prior peg ifn rbv therapy l.jpg
Definitions of failure on prior Peg-IFN/RBV therapy failure?

Null response

Relapse

Non-response

2 log10 drop

HCV RNA level

Partial response

Detection limit

Treatment

Adapted from Shiffman M. Curr Gastroenterol Rep 2006;8:46–52Neumann A, et al. Science 1998;282:103–7; De Bruijne J, et al. Neth J Med 2008;66:311–22


Realize telaprevir svr in prior relapsers partial responders and null responders l.jpg
REALIZE (telaprevir): SVR in prior relapsers, partial responders and null responders

Prior relapsers

Prior partialresponders

Prior null responders

*

*

*

*

SVR (%)

*

*

LI T12/PR4826/48

T12/PR4829/49

PR48

4/27

PR48

2/37

LI T12/PR4825/75

T12/PR4821/72

PR48

16/68

LI T12/PR48124/141

T12/PR48121/145

n/N=

*p<0.001 vs PR48; post-hoc analysis

Foster GR, et al. Hepatol Int 2011;5(Suppl. 1):14


Respond 2 boceprevir svr in prior relapsers and partial responders l.jpg
RESPOND-2 (boceprevir): SVR in prior relapsers and partial responders

Prior relapsers

Prior partialresponders

Prior null responders were excluded from RESPOND-2

SVR (%)

BOCRGT

23/57

BOC44/PR4830/58

PR48

2/29

PR48

15/51

BOC RGT

72/105

BOC44/PR4877/103

n/N=

Bacon BR, et al. Hepatology 2010;52(Suppl.):430A


Summary of tripple therapy with daas l.jpg
Summary of Tripple therapy with DAAs responders

  • Only for Genotype 1 Hepatitis C

  • Uses Peg Inf + Ribavirin + DDA

  • Improved response in naïve patients (65-75%)

  • Improved response in prior non-responders

  • Improved response in difficult to treat groups


Slide21 l.jpg
COST responders

  • Cost of treatment

    • genotype 1 £12,782 for 48 weeks treatment

    • genotype 2 or 3 £5,233 for 24 weeks

  • Supportive therapy with:

    • Epoetin - 8000 units twice weekly = £3,216 for 6 months

    • G-CSF - Neupogen 30million units/wk = £1752 for 6 months

  • Cost of addition of DAA £14,000 - £24,000

    • To be confirmed Sept 2011